Beringea backs DCC with £3m

A portion of the capital injection made by Beringea has been used by DCC to acquire Fantex, a UK manufacturer of anti-microbial biocides. Anti-microbial biocides are chemical substances such as germicides, antibiotics, antibacterials and antivirals that are used to deter harmful organisms.

DCC's new purchase is currently developing biodegradable biocides, designed to have a very fast kill rate, for sectors outside of the healthcare industry such as retail.

Company
Founded in 2003, DCC is headquartered in Horsham with a manufacturing plant in Wolverhampton. The company manufactures disposable, anti-microbial hospital cubicle curtains that are designed to destroy harmful pathogens.

DCC's products are designed to combat hospital-acquired infections, which have become more widespread. According to the company, typical fabric hospital curtains have a high probability of developing pathogens such as MRSA and E Coli on their surfaces.

People
John Hawkins is the chairman and CEO of DCC. Beringea partner Stephane Mery led the deal for the firm.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• UK / Ireland
• Healthcare
• United Kingdom
• Beringea Limited
• Acquisition finance